LINFOMA ESPLENICO DE LA ZONA MARGINAL PDF

Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.

Author: Samutaur Dikasa
Country: Thailand
Language: English (Spanish)
Genre: Sex
Published (Last): 14 April 2015
Pages: 355
PDF File Size: 2.65 Mb
ePub File Size: 14.36 Mb
ISBN: 761-5-53788-903-2
Downloads: 80897
Price: Free* [*Free Regsitration Required]
Uploader: Mezitaur

Splenic marginal zone lymphoma: This item has received. Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases.

The patient underwent splenectomy and sustained complete remission for 13 months. Am J Surg Pathol.

Translation

The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or 11 Grupo Asturiano de Linfomas Noviembre chemotherapy alone.

Splenectomy confirmed the diagnosis of splenic MZL and led to resolution of the skin lesions. La proteinuria monoclonal puede conducir a fallo renal. Primary nodal marginal zone lymphomas of splenic and MALT type. Only comments written in English can be processed. The mass was biopsied, and was again shown to be composed of villous lymphoma cells.

Linfoma primario asociado a efusiones: Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. Show more Show less.

Unfortunately, the evidence to guide this practice is still based only on case reports. The histopathology of splenic lymphoma with villous lymphocytes. A previously healthy year-old man was diagnosed with SMZL in April immunophenotype of circulating lymphocytes that was compatible with SMZL with villous lymphocytes. ZAP expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

  DATA VISION 16278 PDF

Linfoma esplénico de la zona marginal

Lincoma Treat Options Oncol. Rituximab monotherapy also controlled the autoimmune thrombocytopenia in one patient. It should be noted that a broader search strategy maarginal used in relation to these last two databases Table 1. Finally, the classification must be histopathologically based because it is the pathologist who, in most instances, makes the initial diagnosis.

For all other comments, please send your remarks via contact us. Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma.

Both patients in the present report received linfima doses of rituximab with an apparent effect on disease control. In this setting, because of the low toxicity profile of rituximab, this monoclonal antibody has emerged as a convenient alternative for treating patients who refuse to undergo splenectomy or who are clinically unfit for esplebico surgical procedure.

You can change the settings or obtain more information by clicking here. CiteScore measures average citations received per document published. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Are you a health professional able to prescribe or dispense drugs?

Para el 20 de febrero – Haverford Township School District. The purpose of this retrospective study was to report our experience on the efficacy of Rituximab as first line treatment in 16 consecutive SMZL patients, diagnosed in our department. The present study demonstrates that rituximab is an effective treatment for SMZL and could be considered as a substitute or alternative to splenectomy.

Because of the rarity of the disease, there is no established standard therapy. A chest CT scan revealed zon enlargement. Catovsky D, Matutes E.

The immunophenotype was compatible with SMZL with villous lymphocytes. Patterns of bone marrow involvement in 58 patients presenting primary splenic esplenifo zone lymphoma with or without circulating villous lymphocytes.

Go to esplejico members area of the website of the AEDV, https: A revised European-American classification of lymphoid neoplasms: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Marginal zone-related neoplasms of splenic and nodal origin. Marginal zone B-cell lymphoma: The present case indicates that treatment with fludarabine is effective for SLVL and recommended as the first-line therapy for elderly patients and those with an aggressive form of the disease.

  AZADIRACHTA EXCELSA PDF

The t 11;18 q21;q21 chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin’s lymphomas of the mucosa-associated lymphoid tissue MALT- type. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t 9;14 p13;q The documents contained in this web site are presented for information purposes only.

Signs and symptoms, mostly related to ypersplenism, are successfully managed by splenectomy. magrinal

Pemphigus Vegetans in the Inguinal Folds. For management of symptomatic SMZL, splenectomy is still considered to be the front-line treatment of choice, since this marginzl has shown survival advantage over chemotherapy.

Linfoma esplénico de la zona marginal:

Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia. Among the complete responders seven patients had also a molecular remission. One CR and seven minor or good haematological esponses were recorded in relapsed patients.

None Sources of funding: Considering the lack of established data regarding this rare and clinically challenging issue, we made a systematic search for indexed articles published on this topic.

A new course of rituximab was administered, using the same schedule as before. Pacientes con F o FC con o sin Rituximab: